Cargando…

The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis

BACKGROUND: Refractory non-malignant ureterostenosis is challenging to treat. The experience to treat the stenosis primarily cause by retroperitoneal fibrosis with the Resonance and Allium metallic stent is still limited. We aim to evaluate the efficacy and safety of these two stents and provide alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Wei, Xing, Tianying, Ou, Tongwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025479/
https://www.ncbi.nlm.nih.gov/pubmed/33827529
http://dx.doi.org/10.1186/s12894-021-00815-6
_version_ 1783675503851339776
author Gao, Wei
Xing, Tianying
Ou, Tongwen
author_facet Gao, Wei
Xing, Tianying
Ou, Tongwen
author_sort Gao, Wei
collection PubMed
description BACKGROUND: Refractory non-malignant ureterostenosis is challenging to treat. The experience to treat the stenosis primarily cause by retroperitoneal fibrosis with the Resonance and Allium metallic stent is still limited. We aim to evaluate the efficacy and safety of these two stents and provide alternative treatment options. METHODS: A retrospective study was conducted for patients with non-malignant ureterostenosis and treated with the Resonance and Allium stents from March 2011 to September 2020 in our department. The efficacy was evaluated by the change of serum creatinine, glomerular filtration rate (GFR), the proportion of GFR of the affected side and hydronephrosis grade. The safety was evaluated by postoperative presence of moderate or severe overactive bladder (OAB), recurrent urinary infection, pain, stent displacement, encrustation and re-obstruction. RESULTS: 33 patients were eligible for the study, including 18 cases treated by the Resonance stents and 15 patients treated by the Allium stents. The patients of two groups had similar age and gender proportion. The cause of ureterostenosis was mainly retroperitoneal fibrosis in both groups but the Resonance group had more idiopathic cases. Follow-up time was significantly longer in the Resonance group than the Allium group (36.2 ± 24.0 vs 9.4 ± 5.0 months, p < 0.001). Both groups showed improvement or maintenance of serum creatinine level, GFR, the GFR proportion of the affected side and hydronephrosis grade after treatment. The Resonance group presented significant higher incidence of moderate or severe OAB, recurrent urinary infection and pain, while the Allium group showed significant more cases of re-obstruction. CONCLUSION: Both the Resonance and Allium stent can relieve the non-malignant refractory ureterostenosis effectively. The Resonance stent may cause more irritable symptoms while the Allium stent may have a higher rate of re-obstruction. The long term efficacy and safety of the Allium stent in treating non-malignant refractory ureterostenosis requires further study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-021-00815-6.
format Online
Article
Text
id pubmed-8025479
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80254792021-04-08 The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis Gao, Wei Xing, Tianying Ou, Tongwen BMC Urol Research Article BACKGROUND: Refractory non-malignant ureterostenosis is challenging to treat. The experience to treat the stenosis primarily cause by retroperitoneal fibrosis with the Resonance and Allium metallic stent is still limited. We aim to evaluate the efficacy and safety of these two stents and provide alternative treatment options. METHODS: A retrospective study was conducted for patients with non-malignant ureterostenosis and treated with the Resonance and Allium stents from March 2011 to September 2020 in our department. The efficacy was evaluated by the change of serum creatinine, glomerular filtration rate (GFR), the proportion of GFR of the affected side and hydronephrosis grade. The safety was evaluated by postoperative presence of moderate or severe overactive bladder (OAB), recurrent urinary infection, pain, stent displacement, encrustation and re-obstruction. RESULTS: 33 patients were eligible for the study, including 18 cases treated by the Resonance stents and 15 patients treated by the Allium stents. The patients of two groups had similar age and gender proportion. The cause of ureterostenosis was mainly retroperitoneal fibrosis in both groups but the Resonance group had more idiopathic cases. Follow-up time was significantly longer in the Resonance group than the Allium group (36.2 ± 24.0 vs 9.4 ± 5.0 months, p < 0.001). Both groups showed improvement or maintenance of serum creatinine level, GFR, the GFR proportion of the affected side and hydronephrosis grade after treatment. The Resonance group presented significant higher incidence of moderate or severe OAB, recurrent urinary infection and pain, while the Allium group showed significant more cases of re-obstruction. CONCLUSION: Both the Resonance and Allium stent can relieve the non-malignant refractory ureterostenosis effectively. The Resonance stent may cause more irritable symptoms while the Allium stent may have a higher rate of re-obstruction. The long term efficacy and safety of the Allium stent in treating non-malignant refractory ureterostenosis requires further study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-021-00815-6. BioMed Central 2021-04-07 /pmc/articles/PMC8025479/ /pubmed/33827529 http://dx.doi.org/10.1186/s12894-021-00815-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Gao, Wei
Xing, Tianying
Ou, Tongwen
The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title_full The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title_fullStr The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title_full_unstemmed The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title_short The Resonance and the Allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
title_sort resonance and the allium ureteral stents in the treatment of non-malignant refractory ureterostenosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025479/
https://www.ncbi.nlm.nih.gov/pubmed/33827529
http://dx.doi.org/10.1186/s12894-021-00815-6
work_keys_str_mv AT gaowei theresonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis
AT xingtianying theresonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis
AT outongwen theresonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis
AT gaowei resonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis
AT xingtianying resonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis
AT outongwen resonanceandthealliumureteralstentsinthetreatmentofnonmalignantrefractoryureterostenosis